ArticleEJNMMI research2026
Biodistribution, radiodosimetry and pharmacokinetics of [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- P2X7 Signaling in Neuroinflammation: Glial Crosstalk, Redox Integration, and Therapeutic Targeting.Journal of molecular neuroscience : MN · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundIncreasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [18F]GSK1482160 for imaging P2X7R were evaluated. The absorbed dose (AD) and effective dose (ED) of nonhuman primates (NHPs) and human adult volunteers were estimated. The total volume distribution (VT) was calculated via the 2-tissue compartment model (2TCM) and Logan plot (LoganAIF).
resultsThere were no adverse events after [18F]GSK1482160 dosing. Radioactivity accumulated predominantly in the hepatobiliary system, kidney, spleen, and brain. Organ dosimetry revealed the liver as the critical organ with a mean AD of 30.1 µGy/MBq, followed the adrenals at 22.8 µGy/MBq. The overall ED of the female and male human volunteers were 10.9 µSv/MBq and 8.88 µSv/MBq, respectively. [18F]GSK1482160 has the ability to cross the blood–brain barrier and is distributed throughout the whole brain with low region specificity. The 2TCM and LoganAIF models had good correlation and agreement, and the input functions of the image-derived and blood-sampling methods had good correlation but poor correspondence. The AD and ED produced by [18F]GSK1482160 were within typical levels for fluorine-18-labeled tracers.
conclusions[18F]GSK1482160 is a safe PET tracer with hepatorenal metabolism and it is up to 250 MBq (6.7 mCi) for human adults of [18F]GSK1482160 can be administered of a total effective dose of 2.73 mSv (0.273 rem) with the critical organ, the liver, receiving the maximum allowed exposure of 50 mSv (5 rem) in accordance with ICRP 103 recommendations. 2TCM and LoganAIF using a blood-sampling input function with blood metabolite correction are accurate methods for quantifying the tracer binding of P2X7R in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.